Kisspeptin Research Overview (also known as Metastin, KP-54, KISS1 peptide, Kisspeptin-10, KP-10)
A naturally occurring neuropeptide that activates GnRH (gonadotropin-releasing hormone) neurons in the hypothalamus, driving the upstream regulation of reproductive hormones. Studied for its role in fertility regulation, sex hormone axis support, and neuroendocrine signaling in both male and female reproductive research.
What Is Kisspeptin?
Kisspeptin is a family of neuropeptides processed from the KISS1 gene product that serve as the essential upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Discovered in 2003, Kisspeptin neurons in the hypothalamus receive signals from sex steroids, energy status, and circadian systems and translate them into GnRH pulses governing reproduction. Without Kisspeptin signaling, the entire reproductive axis is silent.
Role in Reproductive Physiology
Kisspeptin neurons in two hypothalamic populations integrate hormonal feedback and environmental signals to modulate GnRH secretion frequency and amplitude. Inactivating mutations in KISS1 or its receptor produce complete hypogonadotropic hypogonadism in humans, establishing Kisspeptin as the master regulator of fertility. Its signaling is also responsive to energy availability — leptin, ghrelin, and metabolic status all modulate Kisspeptin neuron activity, explaining why extreme undernutrition suppresses reproductive function.
Clinical Research
Kisspeptin-10 and Kisspeptin-54 are in clinical trials for infertility treatment, IVF ovulation triggering, and hypothalamic amenorrhea — where Kisspeptin infusion restores LH pulsatility and menstrual function in women with stress- or exercise-related loss of reproductive cycling.
Quick Reference
| Literature-Reported Dose Range | 50–200 mcg |
| Literature-Reported Frequency | 2-3x/week |
| Literature-Reported Cycle Length | 2-4 weeks |
| Literature-Reported Washout | 4+ weeks |
| Storage | Fridge 2-8°C, 7-14 days |
| Sites Reported in Studies | Belly, thigh, arm |
| Timing | Morning preferred |
Research Indications
Reproductive Health
Hypogonadotropic Hypogonadism
Research demonstrates kisspeptin can restore reproductive hormone secretion in patients with functional or congenital hypogonadotropic hypogonadism.
IVF Ovulation Trigger
Kisspeptin-54 successfully triggers oocyte maturation in IVF with safer profile than hCG, particularly for OHSS high-risk patients.
Hypothalamic Amenorrhea
Clinical trials show kisspeptin can restore reproductive hormone pulsatility in women with hypothalamic amenorrhea.
Sexual Health
Hypoactive Sexual Desire Disorder
RCTs demonstrate kisspeptin modulates sexual brain processing and enhances libido markers in both men and women with HSDD.
Sexual Brain Processing
Brain imaging reveals kisspeptin activates sexual arousal centers while deactivating self-monitoring regions.
Libido Enhancement
Clinical evidence shows improvements in sexual desire, arousal, and satisfaction measures with kisspeptin administration.
Metabolic
Energy Metabolism
Preclinical research suggests kisspeptin signaling influences energy expenditure and locomotor activity.
Glucose Homeostasis
Animal studies indicate kisspeptin receptor signaling affects glucose tolerance and insulin sensitivity.
Body Composition
Research shows kisspeptin signaling may influence body weight regulation and adiposity, particularly in females.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Gonadotropin stimulation | 100-200mcg | 2-3x/week | SubQ |
| Fertility support | 0.4-1.0 nmol/kg | As directed | SubQ (KP-54) |
| Sexual function (clinical) | 1 nmol/kg/h | 75 min infusion | IV |
| Research protocols | 0.3-10 nmol/kg | Variable | IV or SubQ |
Timing
Recommended administration window: morning preferred. Typical onset: 2-5 hours for LH surge.
Peptide Interactions
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
Kisspeptin stimulates GnRH release, working upstream in the reproductive axis
Kisspeptin may serve as safer alternative to hCG for IVF ovulation trigger
May help restore natural testosterone production through LH stimulation
Kisspeptin function is modulated by sex steroids in feedback loops
Reported Research Timeline
01Hours 2–5 (reported in cited studies): lH surge peaks (3-5x baseline)
02Hours 12–14 (reported in cited studies): lH returns to baseline
03Days 1–2 (reported in cited studies): testosterone/estradiol increase
04Weeks 2–4 (reported in cited studies): sexual function improvements possible
05CRITICAL: Do not use daily - causes receptor desensitization
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Use sterile injection technique
AVOID daily administration - causes desensitization
Use 2-3x per week maximum
Caution with cardiovascular disease (vasoconstrictor effects)
Not recommended during pregnancy or breastfeeding
Requires medical supervision for fertility applications
Seek Medical Attention If:
Signs of ovarian hyperstimulation in women
Chest pain or cardiovascular symptoms
Severe headaches or visual disturbances
Persistent injection site reactions
Any concerning hormonal symptoms
Always consult healthcare provider
Quality Indicators
Verified Marker
White, Fluffy Powder
Lyophilized kisspeptin should appear as white to off-white, fluffy powder filling the vial bottom.
Verified Marker
Clear Solution After Reconstitution
When properly mixed with BAC water, solution should be crystal clear with no particles or cloudiness.
Acceptable Range
Slight Compaction
Minor compaction from shipping is acceptable if powder dissolves completely with gentle swirling.
Quality Concern
Discoloration
Any yellow, brown, or unusual coloration indicates oxidation or degradation. Should be white to off-white only.
Quality Concern
Cloudy After Reconstitution
Persistent cloudiness or particles after mixing indicate degraded or contaminated peptide.
Research Citations
- Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder
Comninos, A.N., Wall, M.B., Demetriou, L., et al., 2023, JAMA Network Open - Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder
Comninos, A.N., Wall, M.B., Demetriou, L., et al., 2022, JAMA Network Open - Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization
Jayasena, C.N., Abbara, A., Comninos, A.N., et al., 2014, Journal of Clinical Investigation - Use of kisspeptin to trigger oocyte maturation during in vitro fertilisation (IVF) treatment
Abbara, A., Eng, P.C., Phylactou, M., et al., 2022, Frontiers in Endocrinology - Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54
de Roux, N., Genin, E., Carel, J.C., et al., 2003, Proceedings of the National Academy of Sciences - The GPR54 gene as a regulator of puberty
Seminara, S.B., Messager, S., Chatzidaki, E.E., et al., 2003, New England Journal of Medicine - Impaired kisspeptin signaling decreases metabolism and promotes glucose intolerance and obesity
Tolson, K.P., Garcia, C., Yen, S., et al., 2014, Journal of Clinical Investigation - Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system
Mead, E.J., Maguire, J.J., Kuc, R.E., Davenport, A.P., 2007, British Journal of Pharmacology - KISS1/KISS1R in cancer: Friend or foe?
Guzman, S., Brackstone, M., Radovick, S., Babwah, A.V., Bhattacharya, M.M., 2012, Frontiers in Endocrinology - Potent Vasoconstrictor Kisspeptin-10 Induces Atherosclerotic Plaque Progression and Instability
Dong, F., Zhao, Y., Li, W., et al., 2017, Journal of the American Heart Association - Emerging Therapeutic Potential of Kisspeptin and Neurokinin B
Mills, E.G.A., Dhillo, W.S., Comninos, A.N., 2024, Endocrine Reviews - Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans
Abbara, A., Horton, R., Turnbull, P., et al., 2025, eBioMedicine
Research Focus
GnRH regulation, Fertility, LH/FSH stimulation, Puberty, Hypothalamic signaling, Reproductive health
Verified Vendors Carrying Kisspeptin
Frequently Asked Questions
What should researchers watch for with Kisspeptin?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Kisspeptin?
Hours 2–5 (reported in cited studies): lH surge peaks (3-5x baseline)
How is Kisspeptin typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →